Charcot Midfoot

  • W. Bret Smith
  • Justin Daigre


Charcot arthropathy (CA) is well established in the literature as a destructive and disabling condition of the foot and ankle. A defining characteristic of CA is the initial insidious, cumulative onset of clinical symptoms, which are often uncorrelated with negative radiographic observation. Quite often, affected neuropathic patients are oblivious to recurrent tissue microtrauma, leading to disruption of bony architecture, structural instability, recurrent plantar ulceration, and ultimately increased amputation risk. In its most benign form, the classic rocker-bottom CA midfoot deformity can have a profound negative effect on patient function and quality of life. As an advanced pathology, CA can lead to severe infection with a reported 28–37% increase in patient mortality.


Charcot midfoot Charcot beaming Rocker-bottom foot Neuroarthropathy Charcot wedge resection 


  1. 1.
    Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45(5 Suppl):S1–66.CrossRefGoogle Scholar
  2. 2.
    Molines L, Darmon P, Raccah D. Charcot’s foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab. 2010;36(4):251–5.CrossRefGoogle Scholar
  3. 3.
    Saltzman CL, Hagy ML, Zimmerman B, Estin M, Cooper R. How effective is intensive nonoperative initial treatment of patients with diabetes and Charcot arthropathy of the feet? Clin Orthop Relat Res. 2005;(435):185–90.Google Scholar
  4. 4.
    Wukich DK, Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complicat. 2009;23(6):409–26.CrossRefGoogle Scholar
  5. 5.
    Capobianco CM, Stapleton JJ, Zgonis T. The role of an extended medial column arthrodesis for Charcot midfoot neuroarthropathy. Diabet Foot Ankle. 2010;1(0).Google Scholar
  6. 6.
    Boyko EJ, Ahroni JH, Cohen V, Nelson KM, Heagerty PJ. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care. 2006;29(6):1202–7.CrossRefGoogle Scholar
  7. 7.
    Pakarinen TK, Laine HJ, Maenpaa H, Mattila P, Lahtela J. Long-term outcome and quality of life in patients with Charcot foot. Foot Ankle Surg. 2009;15(4):187–91.CrossRefGoogle Scholar
  8. 8.
    Sohn MW, Lee TA, Stuck RM, Frykberg RG, Budiman-Mak E. Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone. Diabetes Care. 2009;32(5):816–21.CrossRefGoogle Scholar
  9. 9.
    Sohn M-W, Stuck RM, Pinzur M, Lee TA, Budiman-Mak E. Lower-extremity amputation risk after charcot arthropathy and diabetic foot ulcer. Diabetes Care. 2010;33(1):98–100.CrossRefGoogle Scholar
  10. 10.
    Eschler A, Gradl G, Wussow A, Mittlmeier T. Late corrective arthrodesis in nonplantigrade diabetic charcot midfoot disease is associated with high complication and reoperation rates. J Diabetes Res. 2015;2015:246792.CrossRefGoogle Scholar
  11. 11.
    Pinzur MS, Sostak J. Surgical stabilization of nonplantigrade charcot arthropathy of the midfoot. Am J Orthop. 2007;36(7):361–5.PubMedGoogle Scholar
  12. 12.
    Pinzur MS. Neutral ring fixation for high-risk nonplantigrade charcot midfoot deformity. Foot Ankle Int. 2007;28(9):961–6.CrossRefGoogle Scholar
  13. 13.
    Brodsky JW. The diabetic foot. In: Coughlin MJ, Mann RA, Saltzman CL, editors. Surgery of the foot and ankle. St Louis: Mosby; 2006. p. 1281–368.Google Scholar
  14. 14.
    Schon LC, Easley ME, Weinfeld SB. Charcot Neuroarthropathy of the Foot and Ankle. Clini Orthopa Relat Res. 349:116–31.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • W. Bret Smith
    • 1
  • Justin Daigre
    • 2
  1. 1.Foot and Ankle Division Palmetto Health-USC Orthopedic Center, Palmetto Health, Department of Orthopedic SurgeryLexingtonUSA
  2. 2.Decatur Morgan Hospital, Decatur Orthopaedic ClinicDecaturUSA

Personalised recommendations